MiMedx Group, Inc. MDXG R2KR3KPHARMA

Q: What is the current share price of MiMedx Group, Inc. (MDXG)?

As of 2026-09-07 16:24 PDT, MiMedx Group, Inc. (MDXG) trades at $4.57 on NasdaqCM. Its 52-week range is $3.09 to $7.96.

Q: What is the market capitalisation of MDXG?

MiMedx Group, Inc. (MDXG) has a market capitalisation of $666.13M on NasdaqCM.

Q: What is the P/E ratio of MDXG?

MDXG trades at a trailing price-to-earnings (P/E) ratio of 114.25. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.93.

Q: What is the return on equity (ROE) of MDXG?

MDXG has a return on equity (ROE) of 2.88%. Its return on capital employed (ROCE) is 22.95%.

Q: Is MDXG a good stock to buy?

This page provides a data-driven analysis of MiMedx Group, Inc. (MDXG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.mimedx.com

Company Profile ↓

$4.57

-37.14% 1Y

Mkt Cap$666.13M

P/E114.25

P/B2.93

52W High$7.96

52W Low$3.09

Book Value$1.48

EPS (TTM)$0.04

Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 22.9%.

Steady Revenue Expansion

Revenue has grown at a 56.5% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.08.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $418.63M (+20.0% YoY); net profit $48.58M.
Trailing 12 Months Year-on-year growth — revenue -34.7%, earnings +14.5%.
5-Year Trend Long-term compounding — revenue CAGR 56.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	56.54%
1 Year:	-34.70%

Compounded Profit Growth

5 Years:	-
1 Year:	14.52%

Stock Price Performance

1 Year:	-37.14%
6 Months:	+1.56%
3 Months:	+22.19%
1 Month:	+9.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 30% of range

$3.09 $7.96

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)60.46 · Neutral

Price Performance

1M+9.33%

3M+22.19%

6M+1.56%

1Y-37.14%

Valuation vs Sector

P/E of 114.25 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Healthy ROCE of 22.9%.
Compounding revenue at 56.5% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 114.2.
Trading 42.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

114.25

Industry PE

25.17

Forward P/E

26.37

PEG Ratio

2.88

Book Value

$1.48

Price to Book

2.93

P/S

1.78

EV/EBITDA

25.18

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

56.54%

Profit 5Y

Revenue (YoY)

-34.70%

Earnings (YoY)

14.52%

Profitability & Returns

ROCE

22.95%

ROE

2.88%

ROA

1.91%

Profit Margin

1.76%

Op Margin

-28.69%

Gross Margin

78.85%

EPS (Latest Qtr)

$-0.10

EPS (TTM)

$0.04

Balance Sheet & Liquidity

Debt/Equity

0.08

Quick Ratio

4.60

Current Ratio

5.33

Debt

$17.21M

Total Assets

$281.00M

Current Assets

$277.47M

Working Capital

$213.21M

Ownership

Promoter Holding

2.14%

Chg in Prom Hold

0.05%

FII / Inst Holding

77.61%

Chg in FII Hold

-0.10%

Financial Snapshot

Enterprise Value

$666.13M

Total Revenue (TTM)

$355.17M

EBITDA

$20.41M

Free Cash Flow

$41.43M

Operating Cash Flow

$46.15M

Shares Outstanding

145.76M

Gross Margin

78.85%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MDXG MiMedx Group, Inc. R2KR3KPHARMA	4.57	114.25	$666.13M	0.00%	22.95%	2.88%	56.54%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	68.80M	80.49M	84.00M	87.86M	84.15M	95.42M	86.96M	92.59M	66.56M	67.44M	88.86M	76.40M	61.74M	53.65M	64.30M	68.55M	59.97M	68.17M	63.07M	58.89M	66.88M	67.69M	71.68M	81.26M	81.71M	84.71M	87.21M	-	-	-	98.61M	113.72M	118.09M	58.99M	64.36M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.68M	18.72M	19.05M	17.37M	19.98M
Gross Profit	46.85M	45.42M	49.95M	56.43M	60.81M	60.77M	72.00M	74.70M	78.45M	74.79M	86.15M	79.60M	82.18M	59.14M	57.69M	75.66M	63.69M	51.71M	45.45M	54.01M	57.73M	50.33M	55.41M	52.95M	48.96M	55.06M	55.50M	59.26M	67.67M	66.92M	71.72M	72.35M	-	-	-	79.92M	95.01M	99.04M	41.62M	44.38M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67.55M	72.82M	77.96M	57.67M	62.85M
Operating Income	-	1.47M	3.56M	4.70M	-	6.18M	7.21M	8.84M	-	2.97M	1.68M	373.00K	-	-13.41M	-17.07M	14.20M	-	-13.74M	-5.86M	-9.71M	-	-6.85M	-410.00K	-1.07M	-9.30M	-9.64M	-7.10M	-340.00K	10.84M	11.12M	13.20M	23.45M	-	-	-	12.37M	22.19M	21.08M	-16.05M	-18.47M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.54M	27.48M	24.30M	-13.31M	-16.93M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-403.00K	478.00K	-	-	-	402.00K	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.01M	22.85M	21.80M	-15.33M	-17.78M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.39M	6.10M	6.60M	-4.47M	-2.94M
Net Income	13.38M	1.20M	1.98M	3.32M	5.48M	6.00M	10.40M	44.05M	4.28M	4.62M	1.80M	-178.00K	-36.22M	-13.27M	-17.21M	12.38M	-7.48M	-4.82M	-8.47M	-19.42M	-16.58M	-8.38M	-1.78M	-2.34M	-10.49M	-10.87M	-8.43M	-4.98M	1.20M	8.53M	9.26M	17.62M	-	-	-	9.62M	16.75M	15.19M	-10.86M	-14.84M
Diluted EPS	0.11	0.01	0.02	0.03	0.05	0.05	0.09	0.37	0.04	0.04	0.02	0.00	-0.34	-0.12	-0.16	0.11	-0.07	-0.04	-0.08	-0.48	-0.17	-0.09	-0.03	-0.04	-0.11	-0.11	-0.09	-0.06	0.01	0.06	0.06	0.12	-	-	-	0.06	0.11	0.10	-0.07	-0.10
R&D Expense	-	2.50M	3.17M	2.92M	-	4.20M	4.75M	5.48M	-	3.54M	3.72M	3.96M	-	2.90M	2.83M	2.69M	-	2.65M	2.26M	3.37M	-	4.34M	4.06M	4.37M	5.96M	5.51M	5.95M	3.48M	3.67M	3.08M	2.84M	3.01M	2.92M	-	3.33M	3.30M	3.70M	-	4.14M	2.78M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	788.87K	7.76M	27.05M	59.18M	118.22M	187.30M	221.71M	321.14M	359.11M	299.25M	248.23M	-	267.84M	321.48M	348.88M	418.63M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	48.32M	54.63M	60.07M	73.01M
Gross Profit	-	4.40M	21.86M	49.85M	105.56M	167.09M	190.77M	285.92M	322.73M	256.17M	208.90M	-	219.53M	266.84M	288.81M	345.62M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	234.25M	229.73M	229.50M	281.73M
Operating Income	-10.53M	-9.76M	-5.36M	-2.64M	7.10M	24.36M	884.00K	46.22M	-3.92M	-21.16M	-45.40M	-	-14.73M	37.12M	59.31M	63.89M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-10.69M	40.54M	65.35M	78.77M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	4.98M	5.02M	6.46M	1.01M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-19.75M	30.63M	57.29M	66.26M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	206.00K	-36.81M	15.30M	17.68M
Net Income	-11.42M	-10.19M	-7.66M	-4.11M	6.22M	29.45M	390.00K	64.73M	-29.98M	-25.58M	-49.28M	-	-30.20M	58.23M	42.42M	48.58M
Diluted EPS	-	-	-0.09	-0.04	0.05	0.26	0.00	0.56	-0.28	-0.24	-0.77	-	-0.33	0.37	0.28	0.32
R&D Expense	2.75M	2.98M	2.88M	4.84M	7.05M	8.41M	14.34M	17.90M	15.77M	11.14M	11.71M	9.93M	12.70M	12.66M	12.34M	15.10M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	7.35M	27.10M	35.18M	84.69M	109.26M	135.91M	117.27M	121.25M	122.84M	167.17M	202.03M	-	171.43M	239.05M	263.92M	342.65M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	134.20M	164.26M	191.89M	277.47M
Cash & Equivalents	2.65M	1.34M	4.11M	6.75M	44.08M	46.58M	26.30M	30.32M	27.48M	45.12M	69.07M	95.81M	-	65.95M	82.00M	104.42M	166.12M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	13.18M	21.02M	23.81M	25.34M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	43.08M	53.87M	55.83M	75.71M
Total Liabilities	-	1.25M	15.20M	15.18M	11.13M	19.93M	27.93M	69.21M	47.46M	73.19M	132.77M	110.61M	-	189.42M	96.33M	70.81M	86.11M
Current Liabilities	-	1.25M	4.73M	5.02M	9.61M	18.40M	26.78M	60.79M	45.81M	71.55M	67.32M	59.16M	-	43.56M	46.01M	45.59M	64.27M
Long Term Debt	-	-	2.74M	4.01M	0	-	-	-	-	0	61.91M	47.70M	-	48.59M	48.10M	17.83M	16.47M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	48.59M	49.10M	18.83M	17.97M
Total Equity	6.07M	6.10M	11.90M	20.01M	73.57M	89.33M	34.72M	48.07M	73.80M	49.66M	34.40M	-150.00K	-	-17.99M	142.72M	193.11M	256.55M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	113.71M	146.23M	146.93M	148.09M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.16M	-6.66M	-3.33M	-284.00K	16.80M	18.81M	23.85M	62.94M	35.80M	-39.41M	-30.26M	-1.98M	-17.89M	26.77M	66.20M	74.00M
Investing Cash Flow	-151.62K	-702.51K	-637.00K	-3.03M	-12.15M	-678.00K	-11.68M	-5.40M	-9.22M	504.00K	-4.55M	-3.40M	-2.66M	-2.15M	-9.58M	-6.89M
Financing Cash Flow	7.00M	10.14M	6.61M	40.63M	-2.15M	-36.23M	-8.15M	-60.39M	-8.93M	62.86M	61.56M	-3.35M	-580.00K	-8.57M	-34.20M	-5.41M
Capital Expenditure	-	-	-	-	-	-	-	-	-	-	-	-3.22M	-1.51M	-1.99M	-	-
Free Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-5.20M	-19.41M	24.79M	-	-
Share Buybacks	-	-	-	-	-	40.14M	10.40M	68.30M	7.60M	-	900.00K	0	0	9.52M	0	0

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	56.7%	80.8%	84.2%	89.3%	89.2%	86.0%	89.0%	89.9%	85.6%	84.2%	-	82.0%	83.0%	82.8%	82.6%
Operating Margin %	-1,335.2%	-125.8%	-19.8%	-4.5%	6.0%	13.0%	0.4%	14.4%	-1.1%	-7.1%	-18.3%	-	-5.5%	11.5%	17.0%	15.3%
Net Margin %	-1,447.6%	-131.4%	-28.3%	-6.9%	5.3%	15.7%	0.2%	20.2%	-8.3%	-8.5%	-19.9%	-	-11.3%	18.1%	12.2%	11.6%
ROE %	-187.2%	-85.7%	-38.3%	-5.6%	7.0%	84.8%	0.8%	87.7%	-60.4%	-74.4%	32,856.0%	-	167.9%	40.8%	22.0%	18.9%
ROCE %	-172.7%	-43.6%	-17.8%	-3.5%	7.8%	22.3%	1.6%	61.3%	-7.6%	-21.2%	-31.8%	-	-11.5%	19.2%	27.2%	22.9%

Shareholding Pattern

Insiders

2.14%

Institutions

77.61%

Public Float

79.31%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Essex Woodlands Management Inc.	25.56%	28.20M	$126.88M
2	Blackrock Inc.	11.02%	12.15M	$54.70M
3	Trigran Investments Inc	6.50%	7.17M	$32.28M
4	State Street Corporation	5.06%	5.58M	$25.11M
5	Vanguard Capital Management LLC	4.70%	5.19M	$23.34M
6	Nantahala Capital Management, LLC	4.32%	4.77M	$21.45M
7	Paradigm Capital Management	3.69%	4.07M	$18.33M
8	Geode Capital Management, LLC	2.85%	3.14M	$14.15M
9	Goldman Sachs Group Inc	2.42%	2.67M	$12.00M
10	AQR Capital Management, LLC	2.24%	2.47M	$11.10M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MDXG

Google News Sat, 20 Jun 2026

MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOYW5EQi1SeTdPWjgxNHpQbU1fZWw3WXpmbWpHN2hCOWx3ckdMcDZqOHlhVnFYWExUYXBTaU1jbU93U29sNkZiUTBXbGFrVVNxdTZQVHJqdkYxTlpZbkNNY05IZllpRFZweDQwY2xPRXB2d1JRNVdHVWNzb1NvLVFWOXk5OHVuSVdoVFJ2MG…

Google News hu, 16 Apr 2026

$MDXG stock is down 13% today. Here's what we see in our data. - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQcUlaNjhFSl9RcVhSY2p6NkUzckx4QVFCUjdFVEx5cFVULS1mamloQmgzVlhLeWt5RXc5OWlLQTZtZ194Zk9oVVdWeUpWTDV2TWIyZVdoREg4cGc4OVN3RjF0cXVIR0hCNGpOM2lZRkxVLWZLdzh4SWRJckN4ZTROYS1KSnhzOExFOVdBUF…

Google News Wed, 29 Jul 2026

MIMEDX Group (NASDAQ:MDXG) Shares Fall After Q2 Revenue and EPS Slightly Miss Estimates - ChartMill

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNeXpkNy1fdWZ4UDlPQ0p1NlJ4WmVzaUdGSzZPZUFMUDNTanEyUklzOXg2ZF9ERWUwU1dQeDVoWTJ4NS1MR1o3RjhHOHVhRS0teWtkQXF5VXFHVDdGdVNfdkFjT3BjRHJCX3NpRUR2YUxQcy1ZalFHOTExR3BPa0RNRkJGR3ExMjR5ZHVMcF…

Google News hu, 25 Jun 2026

MDXG Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBlRFduRC1iMk9zRUxXd19GZG1obFFFNW0wNUdhWXF0bUh2ZzlGOF96NzNyQWJJb2xmQ1B5VXlPUjEzOWRKUDBUNzZDWWhoT2NralJiOVZQZHJCTDJEUE5lV0tYLTByemlxbDNZNGJDWFhzeFZPa1g3NVFR?oc=5" target="_blank">MDX…

Google News Wed, 27 May 2026

MDXG - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9fOWtsZ3RIVFdjWlNqUDdBVEtJRWJtaFQ1empneVpIUTZIdDdzMVNCQ2ZJcHJjY19UOWl6ZEN5LXRuUHRaU1E?oc=5" target="_blank">MDXG</a>  <font color="#6f6f6f">Finviz</font>…

Google News hu, 30 Jul 2026

MiMedx Group: Sanara Deal Comes At A Poor Time - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPdGpEODgtSTVhUkN5VkZzYk51bVV6ZVlOQlB4NUZTZF9pV0ZqZFZ0RVNiRTg3VmlWeGFxMTJsS25CTno1OWRJYU4zak9uaHF1VlVIelE4dUNkdmFjd2R0OHJFb1k1Vl9oWC0xZm90aDR4Qk03ZWotUlVmSWNDTGVObU1xMS1SdE8yRmRscH…

MDXG — Frequently Asked Questions

What is the current share price of MiMedx Group, Inc. (MDXG)?

As of 2026-09-07 16:24 PDT, MiMedx Group, Inc. (MDXG) trades at $4.57 on NasdaqCM. Its 52-week range is $3.09 to $7.96.

What is the market capitalisation of MDXG?

MiMedx Group, Inc. (MDXG) has a market capitalisation of $666.13M on NasdaqCM.

What is the P/E ratio of MDXG?

MDXG trades at a trailing price-to-earnings (P/E) ratio of 114.25. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.93.

What is the return on equity (ROE) of MDXG?

MDXG has a return on equity (ROE) of 2.88%. Its return on capital employed (ROCE) is 22.95%.

Is MDXG a good stock to buy?

This page provides a data-driven analysis of MiMedx Group, Inc. (MDXG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

MiMedx Group, Inc. MDXG R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut - Yahoo Finance

$MDXG stock is down 13% today. Here's what we see in our data. - quiverquant.com

MIMEDX Group (NASDAQ:MDXG) Shares Fall After Q2 Revenue and EPS Slightly Miss Estimates - ChartMill

MDXG Forecast — Price Target — Prediction for 2027 - TradingView

MDXG - Finviz

MiMedx Group: Sanara Deal Comes At A Poor Time - Seeking Alpha

MDXG — Frequently Asked Questions

What is the current share price of MiMedx Group, Inc. (MDXG)?

What is the market capitalisation of MDXG?

What is the P/E ratio of MDXG?

What is the return on equity (ROE) of MDXG?

Is MDXG a good stock to buy?

Explore More